Autres langues iCAD, Inc.

Actions

ICAD

US44934S2068

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
1,48 ^USD	+0,68%		-2,63%	-16,38%

11/04	ICAD, Inc. présente le nouveau Profound Cloud et les fonctionnalités améliorées de la station de travail Profound Detection lors du symposium annuel de la SBI	CI
09/04	ICAD, Inc. et Densitas, Inc. s'associent pour améliorer la santé mammaire de précision grâce à des solutions d'IA de pointe pour la qualité des mammographies, la détection des cancers et l'évaluation des risques.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ICAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium	11/04
ICAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium	11/04
ICAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation	09/04
ICAD, Inc. and Densitas, Inc. Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation	09/04
ICAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting	08/04
ICAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)	03/04
ICAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale	02/04
ICAD, Inc. Announces Commercial Availability of ProFound Cloud	02/04
ICAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists	19/03
Earnings Flash (ICAD) ICAD Posts Q4 Revenue $4.7M, vs. Street Est of $4.3M	12/03
ICAD, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	12/03
ICAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results	12/03
ICad to Present Three Mammography Studies at Radiology Conference; Shares Rise	28/02
ICAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings	28/02
ICAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)	27/02
ICAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024	27/02
ICAD, Inc. Appoints Hedvig Hricak to the Board of Directors	26/02
ICAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference	06/02
ICAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member	30/01
ICAD, Inc. Appoints Michael John Doyle to its Board of Directors	25/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues iCAD, Inc.

Actions

ICAD

US44934S2068

Autres langues

Filtres